CORELEADER COLLA-PAD MODEL CS 03030

K102946 · Coreleader Biotech Co., Ltd. · KGN · May 20, 2011 · SU

Device Facts

• Record ID: K102946
• Device Name: CORELEADER COLLA-PAD MODEL CS 03030
• Applicant: Coreleader Biotech Co., Ltd.
• Product Code: KGN · SU
• Decision Date: May 20, 2011
• Decision: SESE
• Submission Type: Traditional
• Device Class: Class U
• Attributes: Therapeutic

Intended Use

Coreleader Colla-Pad Wound Dressing is indicated for the management of wounds including: partial and full-thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/ undermined wounds, surgical wounds, (donor sites/grafts, post-Mohs surgery, post laser surgery, podiatric, wound dehiscence), trauma wounds (abrasions, lacerations, second-degree burns, skin tears) and draining wounds.

Device Story

Coreleader Colla-Pad is a sterile, absorbent topical wound dressing composed of a porous matrix of cross-linked bovine collagen. Designed for clinical use, the pad is applied directly to acute or chronic wounds with light to heavy exudate. Upon contact with wound exudate, the material transforms into a soft gel sheet that maintains intimate contact with the wound bed. This gel layer helps maintain a moist environment conducive to wound healing. The device is cut to fit the specific size of the wound. It is intended for professional use in managing various wound types, including ulcers, surgical sites, and trauma-related injuries. The device benefits patients by providing a biocompatible, absorbent interface that supports the healing process.

Clinical Evidence

Bench testing only. Biocompatibility testing performed per ISO 10993-11, including systemic toxicity, histological analysis, and blood analysis. Results demonstrated no evidence of hypersensitivity, non-cytotoxicity, no irritation, and no induced inflammatory reaction in test animals.

Technological Characteristics

Porous matrix of cross-linked bovine collagen. Physical cross-linking process maintains structural integrity and biocompatibility. High absorbency; converts to soft gel sheet upon exudate contact. Sterile (gamma-ray radiation, 10^-6 SAL). Form factor: pad, cut-to-fit.

Indications for Use

Indicated for management of partial/full-thickness wounds, pressure/venous/diabetic/chronic vascular ulcers, tunneled/undermined wounds, surgical wounds (donor sites/grafts, post-Mohs/laser, podiatric, dehiscence), trauma wounds (abrasions, lacerations, second-degree burns, skin tears), and draining wounds.

Predicate Devices

• INTEGRA FLOWABLE WOUND MATRIX (K072113)
• INTEGRA MESHED BILAYER WOUND MATRIX (K081635)
• SurgiAid Collagen Wound Dressing (K100927)

Submission Summary (Full Text)

{0}------------------------------------------------

K102946
//s

## 510(k) Summary

MAY 2 0 2011

Coreleader Biotech Co., Ltd. Submitted by: 19F, No. 100, Sec. 1, Sintai 5th Rd., Sijhih, Taipei, Taiwan, 22102 Phone: [phone] FAX: [phone]

Contact Person: Teeming Tsao

September 20, 2010 Date Prepared:

Proprietary Name: Coreleader Colla-Pad

Common Name: Collagen Wound Dressing

Classification: Unclassified

Classification Name: Topical Wound Dressing Pad

Predicate Device: INTEGRA LIFESCIENCES CORP., K072113, INTEGRA FLOWABLE WOUND MATRIX. INTEGRA LIFESCIENCES CORP., K081635, INTEGRA MESHED BILAYER WOUND MATRIX. MAXIGEN BIOTEQ INC., K100927, SurgiAid Collagen Wound Dressing

Coreleader Colla-Pad is comprised of a porous matrix of Device Description: cross-linked bovine collagen. Colla-Pad is made of highly absorbent material that converts to a soft, gel sheet that stays in intimate contact with the wound bed as it absorbs exudate t. The moisture held around the wound by Colla-Pad could provide a favorable wound healing environment. Coreleader Colla-Pad is easy to cut and apply. Cut to fit any size of acute or chronic wounds with light to heavy exudate.

{1}------------------------------------------------

киогфиль

уз

Coreleader Colla-Pad is a sterile topical wound dressing, packed in a foil pouch and a foil package and sterilized by r-ray radiation to a 10to SAL.

Coreleader Colla-Pad is indicated for the management of Intended Use: wounds including: partial and full-thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/ undermined wounds, surgical wounds, (donor sites/grafts, post-Mohs surgery, post laser surgery, podiatric, wound dehiscence), trauma wounds (abrasions, lacerations, second-degree burns, skin tears) and draining wounds.

Coreleader Colla-Pad is made of a porous matrix of Technological Characteristics: cross-linked bovine collagen. It is through physical cross-linking process that the Colla-pad has high biocompatibility and structure is not destroyed. In addition, Coreleader Colla-Pad is made of high absorbent material that converts to a soft, gel sheet that stays in intimate contact with the wound bed as it absorbs exudate. The moisture held around the wound by Colla-Pad could provide a favorable wound healing environment.

> The Coreleader Colla-Pad is biocompatibility. It has been tested and shown on accumulative effects, no evidence of hypersensitivity > non-cytotoxicity and is delay non-irritant. Coreleader Colla-Pad that is according to ISO 10993-11 Test for systemic toxicity, we could conclusion that the blood analysis and histological analysis results show test materials do not induce inflammation reaction of all test animals.

{2}------------------------------------------------

Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo features a stylized abstract symbol that resembles three overlapping human figures or lines, suggesting interconnectedness and support. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular fashion around the symbol, indicating the department's name and national affiliation.

Food and Drug Administration 10903 New Hampshire Avenue Document Control Room -WO66-G609 Silver Spring, MD 20993-0002

MAY 2 0 2011

Coreleader Biotech Co., LTd % Mr. lan Li 19F, No. 100, Sec. 1, Sintai 500 Rd, Sijhih City Taipei 22102 Taiwan

Re: K102946 Trade/Device Name: Coreleader Colla-Pad Regulatory Class: Unclassifed Product Code: KGN Dated: May 2, 2011 Received: May 2, 2011

Dear Mr. Li:

We have reviewed your Section 510(k)_premarket_notification_of_intent_to_market_the_device___ referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807): labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set

{3}------------------------------------------------

Page 2 - Mr. Ian Li

forth in the quality systems (OS) regulation (21 CFR Part 820): and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number [phone] or [phone] or at its Internet address http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm.

Sincerely yours.

Aiz B. R.

ter.

Mark N. Melkerson Director Division of Surgical, Orthopedic and Restorative Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{4}------------------------------------------------

Chapter 4 Indications for Use Statement

K102946

## Indications for Use Statement

510(k) Number (if known):

Device Name: Coreleader Colla-Pad

## Indications for Use:

Coreleader Colla-Pad Wound Dressing is indicated for the management of wounds including: partial and full-thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/ undermined wounds, surgical wounds, (donor sites/grafts, post-Mohs surgery, post laser surgery, podiatric, wound dehiscence), trauma wounds (abrasions, lacerations, second-degree burns, skin tears) and draining wounds.

Prescription Use YES (Part 21 CFR 801 Subpart D)

AND/OR

Over-The-Counter Use NO (21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

(Division Sign-Off)
Division of Surgical, Orthopedic,
and Restorative Devices

4-2

Page 1 of 1

510(k) Number K102946